Phase 3 Clinical Trials With Primary Completion Dates in November 2023
This is a list of Phase 3 trials with primary completion dates in November 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|AGIO||Agios Pharmaceuticals, Inc.||2023-11-01||Phase 3||NCT04770753||A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)|
|AKTX||Akari Therapeutics, Plc||2023-11-01||Phase 3||NCT04784455||Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy|
|AMLX||Amylyx Pharmaceuticals, Inc.||2023-11-01||Phase 3||NCT05021536||Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment|
|ITRM||Iterum Therapeutics plc||2023-11-01||Phase 3||NCT05584657||Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women|
|KOD||Kodiak Sciences Inc.||2023-11-01||Phase 3||NCT05066230||A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)|
|NAMS||NewAmsterdam Pharma Company N.V.||2023-11-01||Phase 3||NCT05142722||Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies|